Nilutamide as Second Line Hormone Therapy for Prostate Cancer After Androgen Ablation Fails
- 1 May 2003
- journal article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 169 (5) , 1742-1744
- https://doi.org/10.1097/01.ju.0000057795.97626.66
Abstract
Purpose: We investigate the prostate specific antigen (PSA) response rate with nilutamide as a second line hormonal agent in patients with advanced prostate cancer in whom androgen ablation...Keywords
This publication has 16 references indexed in Scilit:
- Molecular Biology of the Androgen ReceptorJournal of Clinical Oncology, 2002
- Nilutamide: possible utility as a second-line hormonal agentUrology, 2001
- A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinomaCancer, 2000
- Bicalutamide for advanced prostate cancer: the natural versus treated history of disease.Journal of Clinical Oncology, 1997
- Megestrol Acetate in the Treatment of Hormone Refractory Prostate CancerAmerican Journal of Clinical Oncology, 1997
- The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancerCancer, 1995
- Prostate Specific Antigen Decline after Antiandrogen Withdrawal: the Flutamide Withdrawal SyndromeJournal of Urology, 1993
- Orchiectomy and Nilutamide or Placebo as Treatment of Metastatic Prostatic Cancer in a Multinational Double-Blind Randomized TrialJournal of Urology, 1993
- The Proliferative Effect of “Anti-Androgens” on the Androgen-Sensitive Human Prostate Tumor Cell Line LNCaPEndocrinology, 1990
- Pharmacokinetics of Anandron in patients with advanced carcinoma of the prostateCancer Chemotherapy and Pharmacology, 1988